Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations

Jonathan D. Rohrer a, Gerard R. Ridgway a,b, Marc Modat a,b, Sebastien Ourselin a,b, Simon Mead b, Nick C. Fox a, Martin N. Rossor a, Jason D. Warren a,b

a Dementia Research Centre, UCL Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK
b Centre for Medical Image Computing, University College London, Gower Street, London, WC1E 6BT, UK

A R T I C L E   I N F O
Article info
Article history:
Received 22 July 2009
Revised 26 November 2009
Accepted 22 December 2009
Available online 4 January 2010
Keywords:
Frontotemporal dementia
Frontotemporal lobar degeneration
Progranulin
Tau

A B S T R A C T
Neural network breakdown is a key issue in neurodegenerative disease, but the mechanisms are poorly understood. Here we investigated patterns of brain atrophy produced by defined molecular lesions in the two common forms of genetically mediated frontotemporal lobar degeneration (FTLD). Nine patients with progranulin (GRN) mutations and eleven patients with microtubule-associated protein tau (MAPT) mutations had T1 MR brain imaging. Brain volumetry and grey and white matter voxel-based morphometry (VBM) were used to assess patterns of cross-sectional atrophy in the two groups. In a subset of patients with longitudinal MRI rates of whole-brain atrophy were derived using the brain-boundary-shift integral and a VBM-like analysis of voxel-wise longitudinal volume change was performed. The GRN mutation group showed asymmetrical atrophy whereas the MAPT group showed symmetrical atrophy. Brain volumes were smaller in the GRN group with a faster rate of whole-brain atrophy. VBM delineated a common anterior cingulate–prefrontal–insular pattern of atrophy in both disease groups. Additional disease-specific profiles of grey and white matter loss were identified on both cross-sectional and longitudinal imaging; GRN mutations were associated with asymmetrical inferior frontal, temporal and inferior parietal lobe grey matter atrophy and involvement of long intrahemispheric association white matter tracts, whereas MAPT mutations were associated with symmetrical anteromedial temporal lobe and orbitofrontal grey matter atrophy and fornix involvement. The findings suggest that the effects of GRN and MAPT mutations are expressed in partly overlapping but distinct anatomical networks that link specific molecular dysfunction with clinical phenotype.

© 2009 Elsevier Inc. Open access under CC BY license.

Introduction

The role of neural networks in neurodegenerative disease has attracted much recent interest (Seeley et al., 2006; Seeley et al., 2007; Seeley, 2008; Seeley et al., 2008; Borroni et al., 2008; Seeley et al., 2009) however the mechanisms of neural network breakdown remain poorly understood. Frontotemporal lobar degeneration (FTLD) presents a useful disease model in which to investigate this issue. FTLD is the second most common degenerative cause of young-onset dementia (Pickering-Brown, 2007) and constitutes a clinically, pathologically and genetically diverse group of diseases which produce anatomically restricted patterns of frontal and/or temporal lobe atrophy. Furthermore, in around a third of patients there is an autosomal dominant family history, offering the prospect of charting anatomical changes attributable to a defined molecular change (a disease-causing mutation) in the living brain. In recent years mutations in two genes, microtubule-associated protein tau (MAPT) and progranulin (GRN) have been shown to account for many familial cases of FTLD (Pickering-Brown, 2007; van Swieten et al., 2008). While the clinical spectrum of both MAPT and GRN mutations is heterogeneous, certain features occur more frequently in association with a particular molecular substrate. Patients with MAPT mutations commonly present with behavioural variant frontotemporal dementia (bvFTD) which may be accompanied by a corticobasal syndrome (CBS) or more rarely a progressive supranuclear palsy (PSP) syndrome (van Swieten & Spillantini, 2007). Cognitively, executive dysfunction is widely recognized but patients commonly develop semantic impairment later in the disease (Pickering-Brown et al., 2008) as well as prominent episodic memory difficulties (van Swieten et al., 2007). Patients with GRN mutations also present most commonly with bvFTD and there may be an associated CBS (van Swieten et al., 2008). However, unlike MAPT mutations patients in this group frequently present with primary progressive aphasia (PPA) and GRN mutations are more likely to cause early parietal lobe...
impairment (van Swieten et al., 2008; Pickering-Brown et al., 2008; Beck et al., 2008). Group and single case studies suggest that atrophy in association with GRN mutations is asymmetrical and widespread within the affected hemisphere, involving the frontal, temporal and parietal lobes even in the presymptomatic phase, whilst atrophy in association with MAPT mutations is more symmetrical and relatively restricted within the frontal and temporal lobes (Whitwell et al., 2007; Beck et al., 2008; Rohrer et al., 2008; Whitwell et al., 2009a).

Despite the considerable neurobiological as well as clinical interest in delineating signatures of structural damage associated with FTLD, both to further understanding of regional vulnerability in this group of disorders and to test the hypothesis that the phenomenology of FTLD syndromes reflects specific neural network dysfunction (Seeley et al., 2008; Seeley 2008; Seeley et al., 2009), there are few comparative cross-sectional imaging studies of genetic FTLD (Ghetti et al., 2008; 2007; Beck et al., 2008; Rohrer et al., 2008; Whitwell et al., 2009a) and little is known about the longitudinal changes in patterns of atrophy. Here we investigated the cross-sectional and longitudinal imaging features of GRN- and MAPT-associated FTLD using complementary structural imaging techniques. A particular aim of the study was to capture mutation-associated changes both in cortical regions and in underlying white matter tracts that link cortical regions within distributed neural networks.

Materials and methods

Subjects

The research database of patients with FTLD attending the Specialist Cognitive Disorders Clinic of the National Hospital of Neurology and Neurosurgery, London, UK, between 1992 and 2008 was retrospectively reviewed and all patients with MAPT or GRN mutations were identified. Eleven patients with a MAPT mutation (mean (standard deviation) age at baseline scan 53.5 (5.2)) and nine patients with a GRN mutation (mean (standard deviation) age at baseline scan 53.5 (5.2)) were included in the study: the MAPT group comprised four single patients with 10 + 14, S320F and G389R mutations; the GRN mutation group comprised 8 patients with a 10 + 16 mutation and baseline scan 62.9 (6.1)) were included in the study: the MAPT patients with a GRN mutation (mean (standard deviation) age at baseline scan 53.5 (5.2)) and nine patients with a C31fs mutation, two patients with a Q130fs mutation were identified using the MNI average brain template was generated to provide a measure of brain volume in the whole brain using a semi-automated technique in the MIDAS software package (Freeborough et al., 1997a). For rates of atrophy in patients with longitudinal imaging, serial scans were co-registered and volume change was calculated directly using the boundary shift integral (BSI) (Freeborough et al., 1997b). BSI-derived whole-brain volume changes (BSIs) were expressed as annualized percentage change from the baseline brain volume. Analysis of hemispheric volume was also performed: scans and associated whole-brain regions were initially transformed into standard space by registration to the Montreal Neurological Institute (MNI) Template. The left and right hemispheric regions were defined using the MNI average brain which was split by dividing the whole volume along a line coincident with the interhemispheric fissure. An intersection of each individual’s brain region and the hemispheric regions defined on the MNI template was generated to provide a measure of brain volume in left and right hemispheres. A left/right asymmetry ratio measure was calculated by dividing the left hemisphere volume by the right hemisphere volume. Cross-sectional and longitudinal volumetric data

### Table 1

| Patient | Presenting syndrome | Mutation | Gender | Age at scan | Symptom duration at scan | VIQ | PIQ | RMT words | RMT faces | GNT | VOSP | Executive dysfunction |
|---------|---------------------|----------|--------|-------------|--------------------------|-----|-----|-----------|-----------|-----|------|----------------------|
| MAPT1   | bvFTD              | 10 + 16  | M      | 54.5        | 7.5                      | 91  | 96  | <5th      | <5th      | <5th| <5th | Pass                 |
| MAPT2   | bvFTD              | 10 + 16  | M      | 58.0        | 8.0                      | 97  | 107 | <5th      | <5th      | <5th| <5th | Pass                 |
| MAPT3   | bvFTD              | S203F    | M      | 58.7        | 7.7                      | 107 | 128 | >75th     | >75th     | <5th| <10th| Pass                 |
| MAPT4   | bvFTD              | G389R    | M      | 46.1        | 3.1                      | 77  | 70  | <5th      | <5th      | <5th| >10th| Fail                 |
| MAPT5   | bvFTD              | 10 + 16  | F      | 48.8        | 6.8                      | 83  | 81  | 10-25th   | <5th      | <5th| <50-75th| Pass                |
| MAPT6   | bvFTD              | 10 + 16  | F      | 53.2        | 3.2                      | 90  | 84  | 10-25th   | <5th      | <5th| <50-75th| Fail                |
| MAPT7   | bvFTD              | 10 + 14  | M      | 50.3        | 9.1                      | 100 | 96  | <5th      | <5th      | <5th| <50-75th| Fail                |
| MAPT8   | bvFTD              | 10 + 16  | M      | 52.5        | 5.5                      | 104 | 121 | 5-10th    | 5-10th    | <5th| >75th | Fail                 |
| MAPT9   | bvFTD              | 10 + 16  | M      | 45.9        | 8.9                      | 99  | 93  | <5th      | <5th      | <5th| <10th| Pass                 |
| MAPT10  | bvFTD              | 10 + 16  | M      | 60.7        | 2.7                      | 99  | 105 | <5th      | <5th      | <5th| >10th| Pass                 |
| MAPT11  | bvFTD              | 10 + 16  | F      | 56.8        | 1.8                      | 85  | 97  | <5th      | <5th      | <5th| >50-75th| Pass                |
| GRN1    | bvFTD              | C31fs    | M      | 67.4        | 1.4                      | 84  | 72  | <5th      | <5th      | <5th| <50-75th| Fail                |
| GRN2    | bvFTD              | Q130fs   | F      | 65.5        | 3.5                      | 59  | 74  | <5th      | <5th      | <5th| <5th | Fail                 |
| GRN3    | PPA                | C11fs    | M      | 68.3        | 2.3                      | 85  | 108 | 50-75th   | <5th      | <5th| <5th | Pass                 |
| GRN4    | bvFTD              | Q130fs   | M      | 65.9        | 3.9                      | 107 | 95  | 25th      | <5th      | <5th| <10th| Pass                 |
| GRN5    | PPA                | C11fs    | F      | 63.0        | 5.0                      | 84  | 86  | 10-25th   | <5th      | <5th| <50-75th| Fail                |
| GRN6    | PPA                | S203fs   | M      | 50.6        | 2.6                      | 66  | 98  | 25-50th   | <5th      | <5th| <50-75th| Fail                |
| GRN7    | bvFTD              | C11fs    | M      | 56.4        | 3.4                      | 88  | 80  | 25-50th   | 25-50th   | <5th| >50-75th| Fail                |
| GRN8    | PPA/CBS            | E498fs   | F      | 68.4        | 6.4                      | Unable | 69 | 5-10th | <5th      | <5th | <5th | NT                  |
| GRN9    | CBS                | A199V    | M      | 60.7        | 5.7                      | 61  | Unable | Unable | <5th | <5th | Fail                |

Verbal IQ (VIQ) and Performance (PIQ) scores are taken from the WAIS-R. Recognition Memory Test (RMT) for Words and Faces, Graded Naming Test (GNT) and Visual Object and Space Perception (VOSP) battery results are quoted in percentile scores where a score below the 5th percentile is considered impaired. Executive function tasks are the Weigl or Wisconsin Modified Card Sorting Tasks or the Stroop task and are quoted as pass or fail.
were analysed statistically using STATA 10.0 (StataCorp, College Station, TX) by examining contrasts between the group means using a linear regression model. 95% bias-corrected bootstrap confidence intervals with 1000 replicates were used.

Voxel-based morphometry (VBM) was performed on the baseline images using SPM5 software (http://www.fil.ion.ucl.ac.uk/spm) with default settings for all parameters. The images underwent an initial segmentation process in SPM5 which simultaneously estimated transformation parameters for warping grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF) tissue probability maps (TPMs) onto the images. The native space GM and WM segments were then rigidly spatially normalised, using just the rotations and translations from the inverse of the TPM transformation, and resampled to 1.5 mm isotropic resolution. These “imported” images were then iteratively warped to an evolving estimate of their group-wise GM and WM average template using the DARTEL toolbox (Ashburner, 2007; Ashburner et al., 2009). The GM and WM segmentations were then normalised using the final DARTEL transformations and modulated to account for volume changes. Finally, the images were smoothed using a 6 mm full-width at half-maximum (FWHM) Gaussian kernel. Linear regression models were used to examine differences in GM and WM volume between the groups. Voxel intensity, V, was modelled as a function of group, and subject age and total intracranial volume (TIV) were included as nuisance covariates. Separate analyses were performed on the grey matter and white matter segments. Maps showing statistically significant differences between the groups were generated, correcting for multiple comparisons in the disease group-control comparisons by thresholding the images of t-statistics to control the False Discovery Rate (FDR) at a 0.001 significance level. For disease group comparisons maps were generated uncorrected at a 0.001 significance level. Statistical parametric maps were displayed as overlays on a study-specific template, created by warping all native space whole-brain images to the final DARTEL template and calculating the average of the warped brain images. In order to visualise hemispheric asymmetries, we performed two VBM analyses: firstly with all images in their native space; and secondly, with native images flipped in the midsagittal plane within SPM5, such that the most severely affected cerebral hemisphere was on the same side in each patient. An image was selected for flipping if it had a hemispheric asymmetry index outside the control range and more severe right hemisphere atrophy (i.e., images were flipped such that any asymmetric atrophy was displayed on the left): four images from the GRN group and three from the MAPT group met criteria for flipping.

For those patients with longitudinal imaging (6 MAPT patients and 4 GRN patients) we performed non-linear registration of each follow-up image to its corresponding baseline using a multi-scale viscous fluid algorithm (Crum et al., 2003) with a Normalised Mutual Information objective function (Crum et al., 2005). Image pairs were first flipped such that the most severely affected cerebral hemisphere was on the same side in each patient as with the VBM analysis. We computed maps of the fluid registration Jacobian determinants, encoding the relative volume change from baseline to follow-up, which can be analysed using SPM, following Scahill et al. (2002). These ‘Voxel Compression Maps’ (VCMs) were log-transformed as in Scahill et al., but instead of separating out expansion and contraction before smoothing, we separated each subject’s VCM into GM, WM and CSF components according to which tissue segment had the highest probability at each voxel. The sets of tissue-specific VCMs were then spatially normalised using the DARTEL transformations and smoothed using a 6 mm FWHM Gaussian kernel as used for the VBM analysis. The GM and WM analysis masks from the cross-sectional analysis were reused, as was the average template for overlaying results. Voxel-wise statistical analysis was then performed using SPM5, with a linear regression model comprising group indicator variables and nuisance covariates of age, TIV, and inter-scan interval.

Results and discussion

Results

Volumetric data

Whole-brain volumes and rate of atrophy. Baseline brain volumes were smaller in both disease groups compared to healthy controls and mean brain volume was significantly smaller in the GRN group compared to the MAPT group (Table 2). Rates of whole-brain atrophy were significantly greater in the GRN group with no overlap with the MAPT group (Table 2, Fig. 1).

Hemisphere volumes. Baseline mean left and right hemisphere volumes were smaller in the disease groups than the controls and mean left hemisphere volume was significantly smaller in the GRN group compared to the MAPT group, with a trend to smaller mean right

Table 2

Volumetric cross-sectional and longitudinal data.

|                      | MAPT mutations | GRN mutations | Controls |
|----------------------|----------------|---------------|----------|
| Whole-brain volume (ml) | 1117.3 (1079.6, 1162.5) | 996.8 (914.0, 1099.2) | 1230.5 (1180.2, 1272.6) |
| Whole-brain BSI atrophy rate (%/yr) | 1.4 (0.9, 1.9) | 3.4 (2.8, 4.0) | 0.3 (0.1, 0.4) |
| Left hemisphere volume (ml) | 553.5 (536.4, 573.4) | 496.4 (460.8, 545.4) | 605.2 (581.3, 626.3) |
| Right hemisphere volume (ml) | 552.0 (531.8, 574.9) | 489.8 (437.0, 562.1) | 605.9 (581.6, 625.3) |
| Left/right hemisphere ratio | 1.00 (0.99, 1.02) | 1.03 (0.93, 1.15) | 1.00 (0.99, 1.01) |

*p < 0.05 disease group significantly worse than Controls.

b p < 0.05 GRN mutation group significantly worse than MAPT mutation group.

Fig. 1. Annualized rates of whole-brain atrophy (as measured using the boundary shift integral) in the MAPT mutation (diamonds) and GRN mutation (triangles) groups as well as the controls (circles).
hemisphere volume in the GRN group \((p = 0.07)\) (Table 2, Fig. 2A). The overall mean left/right asymmetry ratio was similar in all three groups, however individual cases in the GRN group were highly asymmetrical with all cases falling outside of the control range (Fig. 2A), whereas individual cases in the MAPT group were most often symmetrical with a few cases just falling outside the control range. Only a single GRN patient (GRN5) fell within the range of values of the MAPT group. Furthermore, in the patients with longitudinal imaging, GRN cases became more asymmetric as the disease progressed whilst MAPT patients remained similarly symmetrical (Fig. 2B).

**VBM data**

Grey matter atrophy in disease groups versus controls. Patterns of grey matter atrophy differed in the MAPT and GRN groups compared to healthy controls. The GRN group analysis on unflipped images showed an overall pattern of symmetrical brain atrophy including frontal, temporal and parietal lobes, cingulate cortex and thalamus. However, this result obscures any asymmetries in favour of left or right hemisphere at individual subject level: after flipping of images so that all patients had the most affected hemisphere in the same orientation the true asymmetry of GRN disease was apparent (Fig. 3). The most significant areas of grey matter atrophy were in the inferior frontal lobe, dorsal insula, superior and middle temporal gyri, dorsal anterior cingulate cortex, precuneus and inferior parietal lobe. In contrast, the MAPT group analysis on flipped images revealed a distinct symmetrical pattern of atrophy including anterior and medial temporal lobes, orbitofrontal cortex and ventral insula with less involvement of the anterior cingulate (Fig. 3).

White matter atrophy in disease groups versus controls. In the GRN group compared to controls, the white matter VBM analysis showed most significant involvement of intrahemispheric long association tracts including inferior longitudinal fasciculus, superior longitudinal fasciculus, inferior fronto-occipital fasciculus and cingulum. There was additional involvement of the corpus callosum and brainstem tracts, particularly in the pons (Fig. 3). In the MAPT group compared to controls, the most significant areas of white matter loss lay in the fornices bilaterally with less marked involvement of the uncinate fasciculus (Fig. 3).

GRN versus MAPT group comparisons. Comparing the two mutation groups directly in the flipped VBM analysis (Fig. 4) revealed mutation-associated atrophy profiles involving brain regions previously identified in the control comparison. The GRN group had more marked and asymmetric grey matter loss in inferior frontal lobe, dorsal insula, posterior temporal and inferior parietal lobes and precuneus, and more marked and similarly asymmetric white matter loss in superior longitudinal fasciculus and cingulum. The MAPT group had more marked grey matter loss in the anterior and medial temporal lobes bilaterally and more prominent involvement of the fornices (Fig. 4).

Longitudinal non-linear registration data

Differential patterns of longitudinal volume loss in the two mutation groups were similar to those seen in the cross-sectional VBM analysis (Fig. 5). The GRN group showed longitudinal volume loss asymmetrically involving mainly the inferior frontal, superior temporal, and inferior parietal lobes, precuneus and cingulate cortex as well as the long association white matter tracts. The MAPT group

![Fig. 2. Left/right hemisphere volume ratio in the three groups (A) and in patients with longitudinal imaging as a function of disease duration i.e. time from symptom onset (B).](image-url)
showed longitudinal volume loss symmetrically involving the anteromedial temporal lobes, orbitofrontal cortex and white matter tracts including the corpus callosum.

Discussion

Using convergent imaging techniques, we have shown that GRN and MAPT mutations are associated with distinct profiles of neuronal loss affecting distributed cortical areas and their white matter connections. GRN mutations are associated with asymmetric atrophy of frontal, insular, cingulate, parietal and temporal areas linked by intrahemispheric long association tracts, while MAPT mutations are associated with more restricted but bi-hemispheric atrophy of anteromedial temporal and orbitofrontal areas linked via the fornices and uncinate fasciculi. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolution is more rapid in GRN- than MAPT-associated FTLD, as predicted from the more distributed cerebral damage associated with GRN mutations. Moreover, the degree of asymmetry increases over time in the GRN- (but not the MAPT) associated cases: in conjunction with the evidence presented here for asymmetric longitudinal intrahemispheric volume loss, this increasing asymmetry implies that the pathological process in GRN-associated FTLD is focused within the maximally affected hemisphere. Disease evolutio
molecular abnormality: the atrophy profile of MAPT mutations is consistent with involvement of a ventral orbitofrontal–medial temporal–ventral insula network while the atrophy profile of GRN mutations is consistent with involvement of a more dorsal and asymmetrical anterior cingulate–dorsal insula–temporal–parietal network. This suggests that large-scale neural network dysfunction may be a signature of specific molecular pathologies within the FTLD spectrum. The genetically defined networks identified here are aligned with anatomically similar functional networks delineated in functional connectivity and resting-state network fMRI studies of healthy individuals (Beckmann et al., 2005; Damoiseaux et al., 2006; Margulies et al., 2007; Seeley et al., 2009). Network dysfunction here may provide a neuropathological bridge between molecular dysfunction and clinical phenotype in different genetically mediated forms of FTLD: clinically, MAPT mutations produce behavioural symptoms (especially disinhibition) and later semantic impairment consistent
with involvement of the ventral behavioural–semantic network (Seeley et al., 2009); while GRN mutations may produce bvFTD (with early involvement of the dorsal network in the right cerebral hemisphere), progressive aphasia (with early involvement of the dorsal network in the left cerebral hemisphere) or a corticobasal syndrome (with early involvement of more posterior parts of the dorsal network in either hemisphere).

A crucial unsolved question concerns the mechanisms whereby different molecular lesions may produce strikingly dissimilar patterns of neural network breakdown. There are three interrelated pathophysiological issues here: firstly, how one mutation produces asymmetrical cerebral damage and another more symmetrical damage; secondly, how these distinctive patterns of atrophy are maintained or amplified as the disease evolves; and finally, how phenotypic variation arises such that a particular mutation may selectively damage different cerebral hemispheres even between members of the same family (Beck et al., 2008). The variable clinical presentation of genetic FTLD suggests that molecular lesions do not specify a precise initial anatomical locus of brain damage: the initiation of disease in a particular brain region may be a stochastic event or could reflect hemispheric vulnerability due to developmental or other environmental factors (Mesulam, 2009). However, the evidence from this study suggests that, once initiated, the pattern of disease evolution and the type of evolution that can occur are constrained by the underlying molecular abnormality. Particular mutations are likely to exert their effects via the patterns of large-scale network connectivity that exist in the healthy brain, with connectivity between homotopic cortical areas (which is variable in different parts of the brain) being a crucial factor in linking a particular molecular lesion with symmetrical or asymmetrical network involvement (Stark et al., 2008). At a molecular level, GRN and MAPT are likely to be differentially toxic to neurons: loss of GRN-mediated trophic support (Eriksen & Mackenzie, 2008) might particularly disrupt long axonal connections within a hemisphere, whereas in MAPT-associated FTLD, toxic gain of function (Gendron & Petrucelli, 2009) and the effects of diffusible tau with local spread to neighbouring brain regions (Brunden et al., 2008; Clavaguera et al., 2009) might lead to relatively restricted damage maximally affecting nearby synapses and local interneuronal populations within a functional brain region.

The concept of large-scale neural network breakdown linked to specific molecular lesions may be relevant to the pathogenesis of a number of neurodegenerative pathologies. Specific mutations within a general category of genetically mediated neurodegeneration (such as GRN or MAPT-associated FTLD) may mediate more fine-grained profiles of brain damage, as suggested by recent evidence within the MAPT spectrum (Whitwell et al., 2009b). The small case numbers in the present study do not allow conclusions to be drawn about such fine-grained mutation specificity, underlining a need for larger mutation cohorts recruited via multiple centres in future studies. A related priority is the identification of earliest network-level changes in presymptomatic mutation carriers. In particular, further work is required to test the hypotheses proposed here and to establish the true status of molecular network dysfunction in the pathogenesis of FTLD and indeed, the broader spectrum of neurodegenerative disease.

Acknowledgments

This work was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centres funding scheme. The Dementia Research Centre is an Alzheimer’s Research Trust Co-ordinating Centre. This work was also funded by the Medical Research Council UK. JDR is supported by a Brain Exit Scholarship. NCF holds an MRC Senior Clinical Fellowship. JDW is supported by a Wellcome Trust Intermediate Clinical Fellowship.

References

Ashburner, J., Friston, K.J., 2009. Computing average shaped tissue probability templates. Neuroimage 45 (2), 333–341.

Ashburner, J. 2007. A fast diffeomorphic image registration algorithm. Neuroimage 38 (1), 95–113.

Beck, J., Rohrer, J.D., Campbell, T., et al., 2008. A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain 131 (Pt. 3), 706–720.

Beckmann, C.F., DeLuca, M., Devlin, J.T., Smith, S.M., 2005. Investigations into resting-state connectivity using independent component analysis. Philos. Trans. R. Soc. Lond. B Biol. Sci. 360 (1457), 1001–1013.

Borroni, B., Alberti, A., Premi, E., et al., 2008. Brain magnetic resonance imaging structural changes in a pedigree of asymptomatic progranulin mutation carriers. Rejuvenation Res. 11 (3), 585–595.

Brunden, K.R., Trojanowski, J.Q., Lee, V.M., 2008. Evidence that non-fibrillar tau causes pathological linked to neurodegeneration and behavioral impairments. J. Alzheimers Dis. 14 (4), 393–399.

Clavaguera, F., Bolmont, T., Crowther, R.A., et al., 2009. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11 (7), 909–913.

Crum, W.R., Hill, D.L.G., Hawkes, D.J., 2003. Information theoretic similarity measures in non-rigid registration. IPMI 378–387.

Crum, W.R., Tanner, C., Hawkes, D.J., 2005 Nov 7. Anisotropic multi-scale fluid registration: evaluation in magnetic resonance breast imaging. Phys. Med. Biol. 50 (22), 5153–5174.

Danoiseaux, J.S., Rombouts, S.A., Barkhof, F., et al., 2006. Consistent resting-state networks across healthy subjects. PNAS 103 (37), 13848–13853.

Eriksen, J.L., Mackenzie, I.R., 2008. Progranulin: normal function and role in neurodegeneration. J. Neurochem. 104 (2), 287–297.

Freeborough, P.A., Fox, N.C., Knitj, R.L., 1997a. Interactive algorithms for the segmentation and quantification of 3-D MRI brain scans. Comput. Methods Programs Biomed. 53, 15–25.

Freeborough, P.A., Fox, N.C., 1997b. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans. Med. Imaging 16 (5), 623–629.

Gendron, T.F., Petrucelli, L., 2009. The role of tau in neurodegeneration. Mol. Neurodegener. 4 (1), 13.

Ghetti, B., Spina, S., Murrell, J.R., et al., 2008. In vivo and postmortem clinicanoanatomical correlations in frontotemporal dementia and parkinsonism linked to chromosome 17. Neurodegeneration. Dis. 5 (3–4), 215–217.

Marguilies, D.S., Kelly, A.M., Uddin, L.Q., et al., 2007. Mapping the functional connectivity of anterior cingulate cortex. Neuroimage 37 (2), 579–588.

Mesulam, M., 2009. Defining neurocognitive networks in the BOLD new world of computed connectivity. Neuro 62 (1), 1–3.

Mori, S., Zhang, J., 2006. Principles of diffusion tensor imaging and its applications to basic neuroscience research. Neuro 51 (5), 527–539.

Pickering-Brown, S.M., 2007. The complex aetiology of frontotemporal lobar degeneration. Exp. Neurol. 206 (1), 1–10.

Pickering-Brown, S.M., Rollinson, S., Du Plessis, D., et al., 2008. Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. Brain 131 (Pt. 3), 721–731.

Rohrer, J.D., Warren, J.D., Barnes, J., et al., 2008. Mapping the progression of progranulin-associated frontotemporal lobar degeneration. Nat. Clin. Pract. Neurol. 4 (8), 455–460.

Scialli, R.L., Schott, J.M., Stevens, J.M., et al., 2002. Mapping the evolution of regional atrophy in Alzheimer’s disease: unbiased analysis of fluid-registered serial MRI. PNAS 99 (7), 4703–4707.

Seeley, W.W., 2008. Selective functional, regional, and neuronal vulnerability in frontotemporal dementia. Curr. Opin. Neurol. 21 (6), 701–707.

Seeley, W.W., Carlin, D.A., Allman, J.M., et al., 2006. Early frontotemporal dementia targets neurons unique to apes and humans. Ann. Neurol. 60 (6), 660–667.

Seeley, W.W., Allman, J.M., Carlin, D.A., et al., 2007. Divergent social functioning in behavioral variant frontotemporal dementia and Alzheimer disease: reciprocal networks and neuronal evolution. Alzheimer Dis. Assoc. Disord. 21 (4), 550–577.

Seeley, W.W., Crawford, R., Rascovsky, K., et al., 2008. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch. Neurol. 65 (21), 146–155.

Seeley, W.W., Crawford, R.K., Zhou, J., et al., 2009. Neurodegenerative diseases target large-scale human brain networks. Neuro 62, 42–52.

Stark, D.E., Marguilies, D.S., Shehzad, Z.E., et al., 2008. Regional variation in interhemispheric coordination of intrinsic hemodynamic fluctuations. J. Neurosci. 28 (51), 13754–13764.

van Swieten, J.C., Heutink, P., 2008. Mutations in progranulin (GRN) as a risk factor for neurodegenerative disease. Lancet Neurol. 7 (10), 965–974.

Whitwell, J.L., Jack Jr, C.R., Baker, M., et al., 2007. Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations. Arch. Neurol. 64 (3), 371–376.

Whitwell, J.L., Jack Jr, C.R., Boeve, B.F., et al., 2009a. Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN. Neurology 72 (9), 1134–1140.

Whitwell, J.L., Jack Jr, C.R., Boeve, B.F., et al., 2009b. Atrophy patterns in IVS10+16, IVS10+3, N279K, S305N, P301L, and V337M MAPT mutations. Neurology 73 (13), 1058–1065.